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Poster Session II S335cytogenetic abnormalities (favorable, intermediate or unfavorable
risk group) based on International Prognostic Scoring System
(IPSS). We evaluated allotransplant outcome in MDS patients
with MK.
Result: A total of 79 MDS patients who underwent allotransplant
were identified. Thirty seven of 79 patients (46.8%) harbored unfa-
vorable karyotypes (23 complex karyotype, 25 abnormal chromo-
some 7). Of 79 patients, 24 (30%) met the criteria of MK. The
median follow-up was 5.1 months (0-242 mo). Twenty-four patients
(30%) relapsed and 59 (74.7%) died during the follow-up duration.
Major causes of death included infection (24%), graft versus host dis-
ease (25%) and relapse (31%). Two-year relapse incidence (RI) and
overall survival (OS) were 36% (95%CI, 23%-49%) and 32% (95%
CI, 22%-43%) respectively. Of 79 patients, patients with MK had
significantly higher 2-year RI (51% VS 28%; p 5 0.01) (95%CI,
28-75% VS 13-43%) and lower 2-year OS (6% VS 41%; p 5 0.02)
(95%CI, 0-24%VS 28-54%) than patients without MK. Due to sig-
nificant overlap betweenMK and unfavorable karyotypes, we further
analyzed the effect of MK in each unfavorable karyotype composite
(unfavorable with MK VS unfavorable without MK). Although the
outcome was not statistically different, patients with both unfavor-
able karyotype and MK had a trend toward higher 2-year RI (51%
VS 38%, hazaard ratio [HR] 1.7, p 5 0.34) and lower 2-year OS
(6%VS 31%,HR 1.5, p5 0.28) compare with patients with unfavor-
able karyotypes without MK.
Conclusion: MK is associated with poor allotransplant outcome
with high relapse incidence and low overall survival in addition to
IPSS unfavorable cytogenetic abnormalities.352
MELPHALAN 140MG/M2 COMBINED WITH TBI2(4)Gy AND FLUDARA-
BINE 125MG/M2 AS CONDITIONING FOR ELDERLY PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES IN UNRELATED BONE MARROW
TRANSPLANTATION IS COMPARABLE IN SAFETY AND EFFECTIVENESS
WITH TBI/CY FOR YOUNGER PATIENTS
Ueki, T., Sato, K., Fujikawa, Y., Shimizu, I., Akahane, D., Sumi, M.,
Ueno, M., Ichikawa, N., Kobayashi, H. Nagano Redcross Hospital,
Nagano, Japan
Background:The optimal conditioning and dosage regimen for un-
related bone marrow transplantation for elderly patients with hema-
tological malignancies remains unknown.
Objective and Methods: Among the 63 cases of unrelated bone
marrow transplantation for hematological malignancies performed
in our department, we compared and examined the safety and effi-
cacy of the most commonly used conditioning regimen for elderly
patients, i.e., fludarabine (Flu) (125mg/m2) + melphalan (Mel)
(140mg/m2) + total body irradiation (TBI) [2(4)Gy] (22 cases; here-
after Flu/Mel/TBI group), with theTBI (12Gy) + cyclophosphamide
(CY) (120mg/kg) regimen (23 cases; hereafter TBI/CY group). For 3
cases in the Flu/Mel/TBI group, TBI was increased to 4Gy from
2Gy due to myelodysplastic syndrome associated with each of mye-
lofibrosis, splenomegaly, and aplastic anemia.
Results: The mean age of patients was 58.5 years (range, 40-66
years) for the Flu/Mel/TBI group and 40 years (range, 21-57 years)
for the TBI/Cy group, with the Flu/Mel/TBI group being signifi-
cantly older (p5 0.002). Acute lymphoblastic leukemia was common
in the TBI/CY group. The number of high risk cases did not signif-
icantly differ between the two groups (Flu/Mel/TBI group, 50%;
TBI/CY group, 30%). There were no differences in the number of
days required for engraftment or to achieve complete donor chime-
rism. Early adverse events higher than grade 3, and bacterial, fungal,
or viral infections within one year were 72.7%, 45.5%, 18.2%, and
45.5% in the Flu/Mel/TBI group, and 73.9%, 26.1%, 17.4%, and
52.2% in the TBI/CY group, with no significant difference between
the groups. Acute and chronic GVHD were observed in 56.5% and
81%of cases in the Flu/Mel/TBI group, and 52.5% and 53.4% in the
TBI/CY group, with the Flu/Mel/TBI group having a significantly
higher incidence of chronic GVHD (p5 0.014). The median obser-
vation period of survivors was 30months for the Flu/Mel/TBI group
and 68 months for the TBI/CY group. Two year overall survival and
relapse-free survival were 72.4% and 59.1% in the Flu/Mel/TBI
group, and 77.5% and 64.1% in the TBI/CY group; and two year
treatment-related mortality and recurrence rate were 14.6% and30.8% in the Flu/Mel/TBI group, and 0% and 35.9% in the TBI/
CY group, with no significant differences between the groups.
Conclusion: Flu/Mel/TBI for elderly individuals with hematologi-
cal malignancies proved to be as effective and safe as TBI/CY for
younger patients.
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A PROSPECTIVE RANDOMIZED STUDY COMPARING REDUCED-INTEN-
SITY CONDITIONING AND MYELOABLATIVE CONDITIONING IN PA-
TIENTS WITH MYELOID LEUKEMIA UNDERGOING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ringden, O.1, Erkers, T.1, Aschan, J.2, Le Blanc, K.3, Hagglund, H.4,
Omazic, B.1, Svenberg, P.1, Ljungman, P.4, Mattsson, J.1,
Remberger, M.1 1Karolinska Institutet, Stockholm, Sweden; 2Karolinska
University Hospital Huddinge, Stockholm, Sweden; 3Karolinska Institu-
tet, Stockholm, Sweden; 4Karolinska University Hospital Huddinge,
Stockholm, Sweden
There have been no randomized studies comparing myeloablative
conditioning (MAC) and reduced-intensity conditioning (RIC) in al-
logeneic hematopoietic stem cell transplantation (HSCT). We
wanted to compare the safety and efficacy of these two regimens.
We performed an open-labeled, randomized, controlled phase-III
trial. Over a 10-year period, adult patients#60 years of age with my-
eloid leukemia were randomised (1:1) to undergo RIC (n 5 18) or
MAC (n 5 19). We included recipients of HLA-A, HLA-B, or
HLA-DRB1-identical unmanipulated grafts from related or unre-
lated donors. The primary endpoint was transplant-relatedmortality
(TRM). Secondary endpoints included relapse, survival, chimerism,
and toxicity.
The RIC patients had faster platelet engraftment (p\0.01), re-
quired fewer erythrocyte and platelet transfusions (p\0.001), and re-
quired less total parenteral nutrition (TPN) than the MAC group
(p\0.01). Cytomegalovirus reactivation was commoner in the
MAC group (14/19) than in the RIC group (6/18) (p5 0.02). Hem-
orrhagic cystitis occurred in eight of the MAC patients and in none
of the RIC patients (p\0.01). Donor chimerism was similar in the
two groups regarding CD19 and CD33, but was delayed for CD3
in the RIC group. Later chimerism status was similar. Incidences
of acute and chronic graft-versus-host disease (GVHD) were similar
in the two groups, but twoMACpatients and no RIC patients died of
GVHD. Five-year TRM was around 11% in both groups, and re-
lapse and survival were not significantly different. TheMACpatients
with intermediate cytogenetic acute myeloid leukemia had a three-
year survival of 73%, as compared to 90% in the RIC patients.
TRMwas lowwith RIC andMAC. Although few patients were in-
cluded, RIC had several advantages such as faster platelet engraft-
ment, fewer transfusions, less TPN, fewer CMV reactivations, and
less hemorrhagic cystitis.
354
OUTCOME OF HIGH-RISK AND REFRACTORY AML/MDS PATIENTS RE-
CEIVING A FLAMSA SEQUENTIAL CHEMOTHERAPY REGIMEN FOLLOWED
BY REDUCED-INTENSITY CONDITIONING (RIC) AND ALLOGENEIC HEM-
ATOPOEITIC STEM CELL TRANSPLANTATION (allo-HSCT)
Detrait, M.1, Chevallier, P.2, Sobh, M.1, Guillaume, T.2, Thomas, X.1,
Morisset, S.1, Tedone, N.1, Delaunay, J.2, Nicolini, F.1, Ducastelle, S.1,
Chelghoum, Y.1, Barraco, F.1, Labussiere, H.1, Mohty, M.2,
Michallet, M.1 1Centre Hospitalier Lyon Sud, Pierre Benite, France; 2Ho-
tel Dieu Hospital, University of Nantes, Nantes, France
This retrospective analysis aimed to assess the outcome of 40 pa-
tients with refractory or high risk AML/MDS who received
FLAMSA sequential chemotherapy. There were 30 males and 10 fe-
males with a median age of 52 years (32-66). Diseases characteristics
were: progressive or refractory disease after rescue treatment for first
relapse (n 5 21), early relapse without any further salvage therapy
(n 5 4), and primary induction failure (n 5 4). The series also in-
cluded 7 patients with high risk MDS and 4 patients in first CR
but having a very poor prognosis. The FLAMSA regimen included
Fludarabine (30 mg/m2/d), cytarabine (2 g/m2/d) and amsacrine
(100mg/m2/d) from day -12 to day -9. After 3 days of rest, a RIC reg-
imen was administered. In 28 patients, the RIC regimen included 4
S336 Poster Session IIGy. TBI, ATG 5mg/kg total dose, and cyclophosphamide 40mg/kg
in case of matched related donors, and 60 mg/kg for unrelated or
mismatched donors. In the remaining 12 patients, TBI was replaced
by I.V. Busulfan 3.2 mg/kg/d for 4 days. Eighteen patients were
transplanted using an HLA identical sibling donor, and 22 received
transplant from an unrelated donor. After allo-HSCT, 39 patients
(97.5%) engrafted. In the CR group (n 5 4), after a median fol-
low-up of 5 months (range, 3-31) all patients were still alive in CR
at last follow-up. In the remaining 36 patients, 9 patients developed
acute GVHD $2 with a cumulative incidence at 3 months of 18%
(95%CI, 10-26). At day 90 post HSCT, 23 (64%) patients achieved
hematological CR, and 14 of the 23 remained inCR at last follow-up.
After a median follow-up of 6 months (range, 1-60), the 2-years
probability of OS was 30% (95%CI, 17-52), and the 2-years proba-
bility of PFS was 29% (95%CI, 17-50). The cumulative incidence of
relapse at 1 year was 25% (95%CI, 18-33). Interestingly, none of the
patients who received Busulfan instead of TBI, relapsed. The cumu-
lative incidence of TRM at 3 months and 1 year were 14% (95%CI,
8-20) and 22% (95%CI, 15-29), respectively.
In the multivariate analysis there was a significantly worsened PFS
in patients who received transplant from amismatched donor (HR5
3.6; [95%CI, 1.3-10] p 5 0.01). Also, when considering disease re-
lapse, there was a highly significant impact of the type of RIC regi-
men (in favour of a FLAMSA regimen without TBI (HR 5 0;
[95%CI, 0-0] p\0.0001). A modified FLAMSA regimen incorporat-
ing I.V. Busulfan instead of TBI is likely to allow better long-term
disease control, warranting prospective evaluation.355
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR HEMATOLOGICAL MALIGNANCIES: FACTORS IMPACTING
ITS OCCURRENCE AND TREATMENT OPTIONS FOR A BETTER MANAGE-
MENT
Michallet, M., Sobh, M., Morisset, S., Detrait, M., Labussiere, H.,
Ducastelle, S., Barraco, F., Chelghoum, Y., Thomas, X., Nicolini, F.E.
Centre Hospitalier Lyon Sud, Pierre Benite, France
To evaluate the different pre- and post-transplantation factors im-
pacting the relapse occurrence after allo-HSCT, and to evaluate fac-
tors impacting the survival post-relapse including the different
treatment options; we retrospectively studied the occurrence of re-
lapse in 345 patients, 198 (57%) males and 147 (43%) females with
a median age of 43 years (range17-66) who received allo-HSCT at
our institution for hematological malignancies between years 2000
and 2011; 205 (59%) from siblings and 140 (41%) form unrelated
donors. At transplantation, there were 148 (43%) patients in first
complete response or first chronic phase (CR1/CP1), 66 (19%) in
CR2/CP2 and 131 (38%)\CR2/CP2; 206 (60%) patients received
a full intensity conditioning and 139 (40%) a reduced intensity one.
The different patients and transplantations characteristics with p
values will be communicated in the future. After HSCT, 336
(97%) patients engrafted. The cumulative incidence of acute
GVHD$2 at 3 months was 35% (95%CI 32-37); the cumulative in-
cidence of extensive and limited chronic GVHD at one year was the
same 15% (95%CI 13-17). After a median follow-up of 11.4 months
(range 4-129), the median overall survival (OS) for the whole popu-
lation was 19months (range 12-33) with a 2-years probability of 47%
(95%CI 42-53). Eighty eight (25.5%) patients relapsed with a cumu-
lative incidence at one and two years of 19% (95%CI 17-21) and
22% (95%CI 20-24) respectively. After relapse, 65 (74%) patients
were treated [21 (32%) received DLI alone, 21 (32%) chemotherapy
alone, 14 (22%) DLI + chemotherapy and 9 (14%) received other
treatment] and 23 (26%) were not treated due to deadly relapse.
The median OS from relapse was 4 months (range 3-5) and the
one year probability of OS in patients who relapsed was 21% (95%
CI 14-31). The multivariate analysis studying the impact of different
variables on the occurrence of relapse showed a negative impact of
disease status [\CR/CP:HR5 3.9 (2.4-6.7), p5 0.0001], a negative
impact of CMV status [D+R-: HR 5 2.4 [1.2-4.7], p 5 0.009] and
a protective impact of cGVHD [HR 5 0.37 (0.2-0.6), p 5 0.0002].
The multivariate analysis studying the pre- and post-relapse vari-
ables on the survival after relapse showed a positive impact of Major
ABO incompatibility: HR 5 0.39 (0.16-0.9), p 5 0.03], a negative
impact of disease status [\CR/CP: HR 5 2.4 (1.3-4.4), p 5 0.003]and a positive survival outcome in patients receiving DLI with or
without chemotherapy [HR 5 0.5 (0.3-0.8), p 5 0.005].
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MAJOR ABO INCOMPATIBLE BONE MARROW TRANSPLANTATION: EF-
FECT OF ISOHEMAGGLUTININ REDUCTION BY PLASMAPHERESIS
Sheppard, D., Tay, J., McDiarmid, S., Huebsch, L.B., Tokessy, M.,
Hamelin, L., Saidenberg, E., Bredeson, C. The Ottawa Hospital, Ottawa,
ON, Canada
Background: The impact of donor-recipient ABO incompatibility
on BMT outcome remains controversial. While some studies have
found no impact, others have found an increased risk of GVHD
and graft failure and an adverse effect on engraftment and OS.
This variability may be partially explained by the lack of consensus
on the management of ABO incompatibility. A common strategy is
to deplete the product of red cells, although this adversely affects
stem cell yield and there is no agreed upon volume that is safe to in-
fuse.
At the Ottawa Hospital (TOH), recipients of major ABO incom-
patible BMT undergo plasmapheresis using 5% albumin when the
product hematocrit is . 10%. Acceptable titres are 1:4 for Anti-A
and 1:8 for Anti-B. The graft is not manipulated. As manipulation
of the marrow is the more common strategy in North America, the
goal of our study is to review the efficacy and safety of this approach
in ABO incompatible BMT.
Methods:We conducted a retrospective review of all major ABO in-
compatible BMT at TOH over a 10-year period from Jan. 1, 2000 to
Dec. 31, 2010. The primary outcome was time to engraftment. Sec-
ondary outcomes included number of plasmaphereses, transfusion
requirements, clinically significant hemolysis and OS.
Results: 26 pts underwent BMT using a major ABO incompatible
donor. 20 pts were male and the median age was 41(11 – 61) years.
Indications for BMT were AML(n 5 11), ALL(n 5 6), NHL(n 5
3), CML(n5 2) and others(n5 4). 19 pts hadmatched sibling donors
and 7 had unrelated donors - 2 of whom were mismatched at 1 anti-
gen. 20 pts underwent myeloablative and 6 underwent reduced-in-
tensity conditioning.
The median number of plasmaphereses was 1(0 – 4). The median
time to neutrophil engraftment for this cohort was 26(17 – 38) days.
This was not significantly different than 110 pts undergoing BMT
without major ABO incompatibility at TOH during the same period
(21 days; 10 – 60; p 5 0.7). Median platelet engraftment (platelet
count . 20 x 109/L) occurred at day 23.5(18 – not reached) in this
cohort and day 21.5(12 – not reached) in the larger cohort (p 5
0.5). The median number of red cell and platelet transfusions were
6(2 – 47) and 24(4 – 140), respectively. No acute hemolytic transfu-
sion reactions were observed. OS at a maximum of 11 years is 52.8%
for pts undergoing major ABO incompatible BMT vs. 42.7% for the
larger cohort.
Conclusions: As an alternative to RBC depletion, recipient plasma-
pheresis is a safe and effective method of managing donor-recipient
major ABO incompatibility prior to BMT.
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TRENDS IN UTILIZATION OF TOTAL BODY IRRADIATION (TBI) PRIOR TO
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) WORLDWIDE
Hong, S.1, Barker, C.2, Klein, J.P.1, Shaw, P.3, Bredeson, C.4,
Angelina, A.14, Rowlings, P.5, Cahn, J.-Y.6, Dabaja, Kharfan-M.7,
Aljurf, M.8, Szer, J.9, Wood, W.A.10, Ahmed, I.11, Gomez-
Almaguer, D.12, Atsuta, Y.13, Pasquini, M.C.1 1CIBMTR, Medical Col-
lege of Wisconsin; 2Memorial Sloan-Kettering Cancer Center; 3The
Children’s Hospital at Westmead; 4Ottawa Hospital Blood & Marrow
Transplant Program; 5Calvary Mater Hospital, New Castle; 6Hospital
A. Michallon, CHU de Grenoble; 7American University of Beirut;
8King Faisal Specialist Hospital & Research Center; 9Royal Melbourne
Hospital; 10University of North Carolina; 11University of New Mexico;
12Hospital Universidad Autonoma de Nuevo Leon; 13Nagoya University
Graduate School of Medicine; 14No Institution
Background:TBI as part of the conditioning regimen prior toHCT
is used primarily to eradicate malignancy and to facilitate engraft-
ment. TBI practices vary widely according to several factors, and
